| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers M > Headlines for MDM Group, Inc. > News item |
MDM Group licenses bird flu oral vaccine from Immunitor
By Lisa Kerner
Erie, Pa., March 14 - MDM Group, Inc. said its Biodefense Division has entered into an agreement with Immunitor USA Inc. to license its new vaccine candidate, Avian Influenza Mucosal Immunity Vaccine (Amivax), for use against H5N1 influenza virus (bird flu).
Immunitor's Amivax consists of killed influenza virus, formulated as a tablet that is stable at room temperature and does not lose biological activity when administered orally, according to a company news release. Unlike traditional vaccines, Amivax is absorbed in the human gut, not in the bloodstream.
Preliminary testing with Amivax has been shown it protects against lethal virus challenge in animals.
MDM said further development work will be conducted to determine the optimally effective dose and immunization schedule in order to select the best commercial formulation of the vaccine.
Under the agreement, Immunitor will continue to direct Amivax testing and production scale-up, while MDM Group will focus on global strategic and marketing alliances. The agreement also calls for MDM to pay royalties to Immunitor on all Amivax sales and sublicensing revenues.
Immunitor USA Inc. is a private company based in Maryland, with government and/or industry alliances in Russia, Canada, Australia, China, Thailand and the United States.
Immunitor is a licensee of Immunitor Corp. Co., Ltd., a private biotech company founded in Thailand.
MDM Group's Biodefense Division discovers and develops vaccines and other countermeasures to support the homeland defense and other stockpile requirements of the U.S. government. MDM is based in Santa Clara, Calif.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.